Cargando…

MON-477 Octreotide and ONO-ST-468, a Novel and Potent Somatostatin Receptor Type-2 (SST2) Agonist, Suppress GH Hypersecretion in the Monkey

Purpose: The verification of efficacy of new drug candidates in primate models may address the translational gap between non-clinical and clinical studies and support the prediction of efficacy in humans. Given this, and to support the evaluation of novel SST2 agonists, a GHRH/arginine-induced GH hy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanaka, Hirotaka, Komagata, Tatsuya, Nishio, Takuya, Ishida, Akiharu, Okada, Hiroki, Katsumata, Seishi, Shinozaki, Koji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550638/ http://dx.doi.org/10.1210/js.2019-MON-477

Ejemplares similares

MON-464 Non-Clinical Profiling of ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, to Support Studies in Humans
por: Komagata, Tatsuya, et al.
Publicado: (2019)

MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells
por: Zhou, Cuiqi, et al.
Publicado: (2019)

Somatostatin, as a Bridge Between the GH-Axis and the Gth-Axis
por: Mizrahi, Naama, et al.
Publicado: (2021)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

MON-415 Pituitary Carcinoma With Sequential Hormone Hypersecretion And A Novel Renal Complication Of Hormone Excess
por: Devine, Kerri, et al.
Publicado: (2019)

SAT-477 Pituitary Carcinoma Arising from a Macroprolactinoma
por: Gammoh, Emily, et al.
Publicado: (2019)

SAT-430 A Phase 1 Study in Healthy Volunteers to Assess the Safety, Tolerability, and Pharmacokinetics of ONO-5788: A Novel Oral Small Molecule Somatostatin Receptor Type-2 Agonist
por: Kaviya, Arpeat, et al.
Publicado: (2019)

Oral Octreotide Capsules Lowered Incidence and Improved Severity of Acromegaly Symptoms Compared to Injectable Somatostatin Receptor Ligands—Results From the MPOWERED Trial
por: Biermasz, Nienke, et al.
Publicado: (2021)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

A Phase 3 Large International Noninferiority Trial (MPOWERED): Assessing Maintenance of Response to Oral Octreotide Capsules in Comparison to Injectable Somatostatin Receptor Ligands
por: Fleseriu, Maria, et al.
Publicado: (2021)

THU050 The Role Of The GH Receptor Polymorphism As Prognostic Factor Of Vertebral Fractures In Acromegaly Patients Resistant To First Generation SSAs And Treated With GH Receptor Antagonist Or Second Generation Somatostatin Ligand
por: Costanza, Flavia, et al.
Publicado: (2023)

SUN-468 Sex Differences in Obesity-Mediated Impairment of Reproductive Function
por: Lainez, Nancy, et al.
Publicado: (2019)

MON-465 SST2 Trafficking Through The Cytoskeleton: Role Of Scaffolding Proteins Filamin A And β-arrestin 2
por: Treppiedi, Donatella, et al.
Publicado: (2019)

MON-468 Selective Inhibition of Epigenetic Pathways Has Anti-Proliferative and Pro-Apoptotic Effects on the Mouse Corticotroph Tumor Cells, AtT20
por: Lines, Kate, et al.
Publicado: (2019)

MON-467 Expression of Somatostatin Receptors in Aggressive Non-Functioning Pituitary Adenomas
por: Soto, Alfonso, et al.
Publicado: (2019)

MON-288 TSH Deficiency in Patients on Somatostatin Analog for TSH-PitNET
por: Illouz, Frederic, et al.
Publicado: (2020)

MON-473 Growth Hormone (GH) Impacts the Gut Microbial Profile: the Presence of Unique Bacterial Genera in Mouse Lines with Altered GH Action
por: Jensen, Elizabeth, et al.
Publicado: (2019)

MON-265 Once-Weekly Somapacitan in Japanese Adults with GH Deficiency Was Well Tolerated, with Similar Efficacy to Daily GH: A Randomized Trial
por: Otsuka, Fumio, et al.
Publicado: (2020)

OR23-05 Human Absorption, Metabolism, Excretion, and Absolute Oral Bioavailability of (14)C-CRN00808, an Orally Bioavailable, Nonpeptide, Selective, Somatostatin Receptor 2 (sST2) Biased Agonist for the Treatment of Acromegaly
por: Madan, Ajay, et al.
Publicado: (2020)

SUN-477 Chronic Variable Stress Worsens Effects of Mild Blast Traumatic Brain Injury on the Stress Response
por: Oyola, Mario, et al.
Publicado: (2019)

FRI308 A Rare Case Of Plurimorphous Plurihormonal Pituitary Neuroendocrine Tumor With LH Hypersecretion
por: Jeevananthan, Athavi, et al.
Publicado: (2023)

MON-437 Enteroendocrine Connections in Congenital Isolated GH Deficiency Due to GHRH Receptor Gene Mutation
por: Oliveira-Santos, Alecia, et al.
Publicado: (2019)

SAT-429 Final Results from the First in Man Phase 1 Clinical Trial of CRN00808, an Orally Bioavailable sst2-Selective, Nonpeptide Somatostatin Biased Agonist, for the Treatment of Acromegaly: Safety, Pharmacokinetics, Pharmacodynamics, and Midazolam Drug Interaction in Healthy Volunteers
por: Madan, Ajay, et al.
Publicado: (2019)

MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

MON-LB47 An International Simulated Use Study (PRESTO) to Evaluate Nurse Preferences Between the Lanreotide Autogel New Syringe and Octreotide Long-Acting Release Syringe
por: Adelman, Daphne T, et al.
Publicado: (2020)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

SUN-LB48 Increased Mortality in Acromegaly Is Mainly Due to Vascular and Respiratory Disease and Is Normalized by Control of Growth Hormone Hypersecretion
por: Orme, Stephen Michael, et al.
Publicado: (2020)

OR23-04 SST5 Expression and USP8 Mutation in Functioning and Silent Corticotroph Pituitary Tumors
por: castellnou, Solene, et al.
Publicado: (2020)

SAT-305 Veldoreotide (COR005) Mechanisms of Action Studies: Comparison to Octreotide and Pasireotide
por: Dasgupta, Pooja, et al.
Publicado: (2020)

SAT-468 Conversion of a Non-Secreting to a Growth Hormone-Secreting Pituitary Adenoma: A Case of Rapid Development of Acromegaly
por: Motwani, Komal, et al.
Publicado: (2019)

MON-307 Prospective, Longitudinal Study of Glucose-Suppressed GH Levels in 87 Acromegaly Patients with IGF-1 Normalization After Surgical Therapy: Prognostic Value of Nadir GH Levels for Long-Term Remission or Recurrence
por: Freda, Pamela, et al.
Publicado: (2020)

MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Labadzhyan, Artak, et al.
Publicado: (2020)

A Case With Adult GH Deficiency Complicated With Osteogenesis Imperfecta: Effect of GH Replacement on Bone Mineral Density
por: Taguchi, Tomomi, et al.
Publicado: (2021)

FRI296 Somatostatin Receptor 5 Staining In Prolactinomas
por: Mehta, Sonal, et al.
Publicado: (2023)

Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly
por: Freda, Pamela, et al.
Publicado: (2021)

GH Is a Component of SASP in Aging Tissue
por: Chesnokova, Vera M, et al.
Publicado: (2021)

Olfactory Neuroblastoma: The Adjunctive Role of Somatostatin Agonists After Surgery
por: Toral, Fernando Pazos, et al.
Publicado: (2021)

SUN-LB47 Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201
por: Seaman, Paul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sf3a267igsnviuvhuhf5374j4g